Implantation of GL261 neurospheres into C57/BL6 mice: A more reliable syngeneic graft model for research on glioma-initiating cells

Yi,Liang; Zhou,Chun; Wang,Bing; Chen,Tunan; Xu,Minhui; Xu,Lunshan; Feng,Hua

doi:10.3892/ijo.2013.1962

Implantation of GL261 neurospheres into C57/BL6 mice: A more reliable syngeneic graft model for research on glioma-initiating cells

Authors:
- Liang Yi
- Chun Zhou
- Bing Wang
- Tunan Chen
- Minhui Xu
- Lunshan Xu
- Hua Feng
View Affiliations

Affiliations: Department of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing, P.R. China, Department of Neurosurgery, Yongchuan District People's Hospital, Chongqing, P.R. China, Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China
Published online on: May 27, 2013 https://doi.org/10.3892/ijo.2013.1962
Pages: 477-484

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have demonstrated that inflammatory cells and inflammatory mediators are indispensable components of the tumor-initiating cell (TIC) niche and regulate the malignant behavior of TICs. However, conventional animal models for glioma-initiating cell (GIC) studies are based on the implantation of GICs from human glioblastoma (GBM) into immunodeficient mice without the regulation of immune system. Whether animal models can mimic the cellular microenvironment of malignancy and evaluate the biological features of GICs accurately is unclear. Here, we detected the biological features of neurosphere-like tumor cells derived from the murine GBM cell line GL261 (GL261-NS) and from primary human GBM (PGBM-NS) in vitro, injected GL261-NS into syngeneic C57/BL6 mouse brain and injected PGBM-NS into NOD/SCID mouse brain, respectively. The tumorigenic characteristics of the two different orthotopic transplantation models were analyzed and the histological discrepancy between grafts and human primary GBM was compared. We found that GICs enriched in GL261-NS, GL261-NS and PGBM-NS exhibited increased GIC potential and enhanced chemoresistance in vitro. GL261-NS was significantly more aggressive compared to GL261 adhesive cells (GL261-AC) in vivo and the enhanced aggression was more significant in syngeneic mice compared to immunodeficient mice. The discrepancy of tumorigenicity between GL261-NS and GL261-AC in C57/BL6 mice was also larger compared to that between PGBM-NS and PGBM-AC in immunodeficient mice. Syngrafts derived from GL261-NS in C57/BL6 mice corresponded to the human GBM histologically better, compared with xenografts derived from PGBM-NS in NOD/SCID mice, which lack inflammatory cells and inflammatory mediators. We conclude that the inflammatory niche is involved in the tumorigenicity of GICs and implantation of GL261-NS into C57/BL6 mice is a more reliable syngeneic graft model for in vivo study on GICs relative to the immunodeficiency model.

View Figures

View References

1.	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
2.	Stiles CD and Rowitch DH: Glioma stem cells: a midterm exam. Neuron. 58:832–846. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Sughrue ME, Yang I, Kane AJ, et al: Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med. 7:842009. View Article : Google Scholar : PubMed/NCBI
5.	Wei J, Barr J, Kong LY, et al: Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 9:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Dziurzynski K, Wei J, Qiao W, et al: Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 17:4642–4649. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Pellegatta S, Poliani PL, Corno D, et al: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 66:10247–10252. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Yu SC, Ping YF, Yi L, et al: Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett. 265:124–134. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Bao S, Wu Q, Sathornsumetee S, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843–7848. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Maes W and Van Gool SW: Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 60:153–160. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Yi L, Xiao H, Xu M, et al: Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol. 232:75–82. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Yi L, Zhou ZH, Ping YF, et al: Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol. 20:1061–1068. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Yang S, Wang B, Guan C, et al: Foxp3⁺IL-17⁺ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol. 89:85–91. 2011.
14.	Beier D, Schulz JB and Beier CP: Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
15.	Galli R, Binda E, Orfanelli U, et al: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69–82. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Krishnamurthy S, Dong Z, Vodopyanov D, et al: Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 70:9969–9978. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Li Z, Bao S, Wu Q, et al: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar
20.	Bayne LJ, Beatty GL, Jhala N, et al: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21:822–835. 2012. View Article : Google Scholar
21.	Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia. 59:1169–1180. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Hussain SF, Yang D, Suki D, Aldape K, Grimm E and Heimberger AB: The role of human glioma-infiltrating microglia/ macrophages in mediating antitumor immune responses. Neurooncol. 8:261–279. 2006.PubMed/NCBI
23.	Wiencke JK, Accomando WP, Zheng S, et al: Epigenetic biomarkers of T-cells in human glioma. Epigenetics. 7:1391–1402. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Hong TM, Teng LJ, Shun CT, Peng MC and Tsai JC: Induced interleukin-8 expression in gliomas by tumor-associated macrophages. J Neurooncol. 93:289–301. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Guryanova OA, Wu QL, Cheng L, et al: Non-receptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 19:498–511. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Lamszus K and Gunther HS: Glioma stem cells as a target for treatment. Target Oncol. 5:211–215. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Chen J, McKay RM and Parada LF: Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 149:36–47. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Li Z, Wang H, Eyler CE, Hjelmeland AB and Rich JN: Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 284:16705–16709. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Wagers AJ: The stem cell niche in regenerative medicine. Cell Stem Cell. 10:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
30.	Ginestier C, Liu S, Diebel ME, et al: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 120:485–497. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Sansone P, Storci G, Tavolari S, et al: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 117:3988–4002. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Weiss WA, Burns MJ, Hackett C, et al: Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 63:1589–1595. 2003.PubMed/NCBI
33.	Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M and Holland EC: mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia. 7:356–368. 2005. View Article : Google Scholar : PubMed/NCBI
34.	Szatmari T, Lumniczky K, Desaknai S, et al: Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97:546–553. 2006. View Article : Google Scholar : PubMed/NCBI
35.	Hatiboglu MA, Wei J, Wu AS and Heimberger AB: Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 5:217–227. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Wei J, Barr J, Kong LY, et al: Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 16:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Ausman JI, Shapiro WR and Rall DP: Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 30:2394–2400. 1970.PubMed/NCBI
38.	Daga A, Orengo AM, Gangemi RM, et al: Glioma immuno-therapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer. 121:1756–1763. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J and Bernier G: BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 29:8884–8896. 2009. View Article : Google Scholar : PubMed/NCBI
40.	Kim R, Emi M and Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology. 121:1–14. 2007. View Article : Google Scholar : PubMed/NCBI